◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › SVA

Sinovac Biotech Ltd. (SVA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

— · DATA UPDATED 2026-07-10

Sinovac Biotech Ltd. (SVA) operates in the — industry. In the fiscal year ended 2025-12-31, SVA reported $386M in revenue and ($60M) in net income.

Interactive charts & full statements →

SVA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$386M$361M$470M$1.5B
Gross Profit$262M$221M$323M$808M
Operating Income (EBIT)($287M)($475M)($605M)($461M)
Net Income($60M)$91M($14M)$114M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVA Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid($3.5B)($947M)($328M)($263M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SVA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$8.5B$12.3B$13.7B$14.1B
Total Liabilities$2.1B$2.0B$1.6B$1.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SVA viewer.

Other Companies in Software & IT Services

← SURGAll stocksSVAC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.